It is an especially exciting time in the advancement of biosimilar medicines technology and treatments for patients. Over the past few years, great progress has been made in the development and approval of more affordable biosimilar versions of innovative therapies that treat some of the most debilitating and serious health conditions. Yet this positive news is dampened by the reality that there remain significant barriers to patient access to important, potentially life-saving medications. To date, the Food and Drug Administration (FDA) has approved nine biosimilars but only three are available to patients.
Please join the Biosimilars Council, a division of the Association for Accessible Medicines, for a lunch briefing that will provide an overview of the biosimilars market to date, the current barriers to patient access and what Congress can do to ensure patients will benefit from these new treatments.
Presenters include:
Craig Burton, Vice President, Policy, Association for Accessible Medicines (Moderator)
Molly Burich, Associate Director, Public Policy, Boehringer Ingelheim
Mark Fleury, Principal of Policy Development and Emerging Science, American Cancer Society Cancer Action Network
Greg Gierer, Senior Vice President for Policy, America’s Health Insurance Plans
Patrick Vallano, Head of Morgantown Research & Development, Mylan
To learn more about policy solutions to ensure patients will benefit from biosimilars, read the AAM brief: The Biosimilar Council Policy Recommendations to Develop a Robust Biosimilars Market in the U.S.